171 related articles for article (PubMed ID: 36307575)
1. Projecting the Epidemiological and Economic Impact of Chronic Kidney Disease Using Patient-Level Microsimulation Modelling: Rationale and Methods of Inside CKD.
Tangri N; Chadban S; Cabrera C; Retat L; Sánchez JJG
Adv Ther; 2023 Jan; 40(1):265-281. PubMed ID: 36307575
[TBL] [Abstract][Full Text] [Related]
2. Global Economic Burden Associated with Chronic Kidney Disease: A Pragmatic Review of Medical Costs for the Inside CKD Research Programme.
Jha V; Al-Ghamdi SMG; Li G; Wu MS; Stafylas P; Retat L; Card-Gowers J; Barone S; Cabrera C; Garcia Sanchez JJ
Adv Ther; 2023 Oct; 40(10):4405-4420. PubMed ID: 37493856
[TBL] [Abstract][Full Text] [Related]
3. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.
Black C; Sharma P; Scotland G; McCullough K; McGurn D; Robertson L; Fluck N; MacLeod A; McNamee P; Prescott G; Smith C
Health Technol Assess; 2010 Apr; 14(21):1-184. PubMed ID: 20441712
[TBL] [Abstract][Full Text] [Related]
4. The effect of model selection on cost-effectiveness research: a comparison of kidney function-based microsimulation and disease grade-based microsimulation in chronic kidney disease modeling.
Hiragi S; Tamura H; Goto R; Kuroda T
BMC Med Inform Decis Mak; 2018 Nov; 18(1):94. PubMed ID: 30413200
[TBL] [Abstract][Full Text] [Related]
5. Projection of the health and economic impacts of Chronic kidney disease in the Chilean population.
Walbaum M; Scholes S; Rojas R; Mindell JS; Pizzo E
PLoS One; 2021; 16(9):e0256680. PubMed ID: 34495980
[TBL] [Abstract][Full Text] [Related]
6. Projected Health and Economic Burden of Comorbid Gout and Chronic Kidney Disease in a Virtual US Population: A Microsimulation Study.
Card-Gowers J; Retat L; Kumar A; Marder BA; Padnick-Silver L; LaMoreaux B; Webber L
Rheumatol Ther; 2024 Jun; ():. PubMed ID: 38836994
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease.
Yarnoff BO; Hoerger TJ; Simpson SK; Leib A; Burrows NR; Shrestha SS; Pavkov ME;
BMC Nephrol; 2017 Mar; 18(1):85. PubMed ID: 28288579
[TBL] [Abstract][Full Text] [Related]
8. Costs and Healthcare Resource Use Associated with Risk of Cardiovascular Morbidity in Patients with Chronic Kidney Disease: Evidence from a Systematic Literature Review.
Darlington O; Dickerson C; Evans M; McEwan P; Sörstadius E; Sugrue D; van Haalen H; Garcia Sanchez JJ
Adv Ther; 2021 Feb; 38(2):994-1010. PubMed ID: 33432542
[TBL] [Abstract][Full Text] [Related]
9. Prevalence, socio-demographic characteristics, and comorbid health conditions in pre-dialysis chronic kidney disease: results from the Manitoba chronic kidney disease cohort.
Chartier MJ; Tangri N; Komenda P; Walld R; Koseva I; Burchill C; McGowan KL; Dart A
BMC Nephrol; 2018 Oct; 19(1):255. PubMed ID: 30305038
[TBL] [Abstract][Full Text] [Related]
10. The impact of chronic kidney disease on developed countries from a health economics perspective: A systematic scoping review.
Elshahat S; Cockwell P; Maxwell AP; Griffin M; O'Brien T; O'Neill C
PLoS One; 2020; 15(3):e0230512. PubMed ID: 32208435
[TBL] [Abstract][Full Text] [Related]
11. Early chronic kidney disease: diagnosis, management and models of care.
Wouters OJ; O'Donoghue DJ; Ritchie J; Kanavos PG; Narva AS
Nat Rev Nephrol; 2015 Aug; 11(8):491-502. PubMed ID: 26055354
[TBL] [Abstract][Full Text] [Related]
12. Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design.
Sugrue DM; Ward T; Rai S; McEwan P; van Haalen HGM
Pharmacoeconomics; 2019 Dec; 37(12):1451-1468. PubMed ID: 31571136
[TBL] [Abstract][Full Text] [Related]
13. Cost-utility analysis of the National Health Screening Program for chronic kidney disease in Korea.
Go DS; Kim SH; Park J; Ryu DR; Lee HJ; Jo MW
Nephrology (Carlton); 2019 Jan; 24(1):56-64. PubMed ID: 29206319
[TBL] [Abstract][Full Text] [Related]
14. Unlocking Potential within Health Systems Using Privacy-Preserving Record Linkage: Exploring Chronic Kidney Disease Outcomes through Linked Data Modelling.
Lim D; Randall S; Robinson S; Thomas E; Williamson J; Chakera A; Napier K; Schwan C; Manuel J; Betts K; Kane C; Boyd J
Appl Clin Inform; 2022 Aug; 13(4):901-909. PubMed ID: 36170880
[TBL] [Abstract][Full Text] [Related]
15. The chronic kidney disease model: a general purpose model of disease progression and treatment.
Orlando LA; Belasco EJ; Patel UD; Matchar DB
BMC Med Inform Decis Mak; 2011 Jun; 11():41. PubMed ID: 21679455
[TBL] [Abstract][Full Text] [Related]
16. Economic burden of chronic kidney disease in Korea using national sample cohort.
Kim SH; Jo MW; Go DS; Ryu DR; Park J
J Nephrol; 2017 Dec; 30(6):787-793. PubMed ID: 28303461
[TBL] [Abstract][Full Text] [Related]
17. Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis.
Hill NR; Fatoba ST; Oke JL; Hirst JA; O'Callaghan CA; Lasserson DS; Hobbs FD
PLoS One; 2016; 11(7):e0158765. PubMed ID: 27383068
[TBL] [Abstract][Full Text] [Related]
18. Definitions of progression in chronic kidney disease--predictors and relationship to renal replacement therapy in a population cohort with a 6 year follow-up.
Marks A; Fluck N; Prescott GJ; Robertson LM; Simpson WG; Smith WC; Black C
Nephrol Dial Transplant; 2014 Feb; 29(2):333-41. PubMed ID: 24081862
[TBL] [Abstract][Full Text] [Related]
19. A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease.
Schlackow I; Kent S; Herrington W; Emberson J; Haynes R; Reith C; Wanner C; Fellström B; Gray A; Landray MJ; Baigent C; Mihaylova B;
Heart; 2017 Dec; 103(23):1880-1890. PubMed ID: 28780579
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
